Diego Pellicer Plans to Become a Fully Integrated Cannabis Company

Diego Pellicer Plans to Become a Fully Integrated Cannabis Company

The company has announced several letters of intent to purchase retail, manufacturing and cultivation assets in Colorado.

October 3, 2019

Colorado Gov. Jared Polis signed H.B. 19-1090 into law this past summer, opening the door for outside investment and ownership opportunities in the state’s cannabis market, and Diego Pellicer is in turn launching an M&A strategy to take its business to the next level.

The company, which primarily functions as a cannabis brand and development company, has announced letters of intent to purchase a series of yet-to-be-named assets in Denver: a 3,300-square-foot retail store, a 2,287-square-foot cannabis-infused product manufacturing facility and two cultivation facilities with a total of just under 30,000 square feet of grow space.

“We have a series of assets that we are pursuing currently, both the ones we’ve announced and ones that are still in the pipeline,” Diego Pellicer CEO Ron Throgmartin told Cannabis Business Times. “We’ve been patiently waiting for the Colorado market to open up business to publicly traded companies, which we are on the OTCQB. We’ve had very close ties in the marijuana industry … in Colorado but we’ve never, until the recent passage of H.B. 1090, had the opportunity to directly profit from the sale of marijuana, and this is a major shift for Diego Pellicer.”

Read more…

Diego Pellicer Worldwide, Inc. Executes Letter of Intent to Purchase a Second Cannabis Cultivation Facility in Denver

Diego Pellicer Worldwide, Inc. aggressively advancing its business model into direct ownership

DENVER (Sept. 25, 2019) – Diego Pellicer Worldwide, Inc. (OTCQB: DPWW), the premium marijuana brand and development company, today announced that it has executed a letter of intent to purchase a second cannabis cultivation facility in Denver. The fully upgraded, 16,279 square-foot cultivation facility produces approximately 2,650 pounds of medical and recreational cannabis per year.

“We have been aggressively implementing our new business model which includes direct ownership in cannabis operations. Diego Pellicer Worldwide has announced letters of intent to purchase a retail location, processing facility, a cultivation facility and now, this second cultivation facility,” said Ron Throgmartin, chief executive officer, Diego Pellicer Worldwide, Inc. “With this second facility, Diego Pellicer Worldwide will have more than 29,000 square feet of space producing more than 4,500 pounds of cannabis each year. We look forward to working with the Colorado Marijuana Enforcement Division to garner approval for Diego Pellicer Worldwide to become a fully licensed cannabis company.”

The letter of intent for the first cannabis cultivation facility in Denver was announced on Sept. 10, 2019. That modern, 13,000 square-foot cultivation facility produces approximately 2,000 pounds of cannabis per year.

The non-binding letter of intent is subject to compliance with the Colorado Marijuana Enforcement Division and House Bill 19-1090. The letter of intent will be followed by a contract once rulemaking for Colorado House Bill 19-1090 has concluded and the Marijuana Enforcement Division has issued regulations guiding the process for public companies and out-of-state investors to apply for cannabis licensing ownership. The completed regulations and application process are expected in November 2019 after the final public comment hearing is held on Oct. 8. Diego Pellicer Worldwide, Inc. has been actively engaged in the rulemaking workgroups, working alongside other stakeholders to assist and help complete the rulemaking process.

A Premium Diego Pellicer Cannabis Experience Begins with Outstanding Products

Diego Pellicer branded stores feature the finest products, concierge quality service in an approachable, world-class environment. Diego Pellicer elevates the cannabis shopping experience featuring premium products both cultivated and selected by experts, ensuring that no matter the location, customers can count on Diego Pellicer to deliver the same exceptional customer service, premium cannabis and competitive pricing.

About Diego Pellicer Worldwide, Inc. (OTCQB: DPWW)

Diego Pellicer Worldwide, Inc. is the premium marijuana brand, retail and management company. In addition to its branded locations in Colorado, the company actively seeks to develop and manage high-end, turnkey cannabis retail stores and grow facilities. When federally legal, DPWW is positioned to become a national, vertically integrated cannabis company. To learn more about how to become a branded Diego Pellicer retailer, cultivator or investor visit www.Diego-Pellicer.com.

Safe Harbor Statement

Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

# # #

CONTACTS:           Suzanne Herrick, Fedoruk & Associates, Inc., 612-247-3079, suzanne@fedorukinc.com

Nello Gonfiantini, Diego Pellicer Worldwide, Inc., 775-690-2188, nello@diego-pellicer.com

 

WEBSITE:               www.diego-pellicer.com

Tuesday, September 24, 2019 Headlines | Marijuana Today Daily News


A bridge crosses the Charles River in between Boston and Cambridge Massachusetts.

Marijuana Today Daily Headlines
Tuesday, September 24, 2019 | Curated by host Shea Gunther

// Cambridge has temporarily banished ‘Big Cannabis.’ Up next: lawsuits (Boston Globe)

// 21 State Attorneys General Urge Congress Protect State Marijuana Programs From Federal Interference (Marijuana Moment)

// Marijuana Policy Project: Banking Bill Means Equity For Minority Businesses (Op-Ed) (Marijuana Moment)


Today’s headlines are brought to you by our friends over at Eaze.com, California’s top one stop website for legal marijuana delivery. If you live in the golden state, swing over to Eaze.com to see if they are active in your area. With deliveries taking place in less than an hour, it’s never been easier to get legal California marijuana delivery. And of course, if you don’t live where Eaze delivers, you can still benefit from all the useful bits of industry insight and analysis they’ve developed using their properly aggregate and anonymized sales data stream.


// Oregon Psilocybin Ballot Campaign Launches Signature Drive With New $150K Donation (Marijuana Moment)

// European Commission approves Epidiolex marketing authorization, GW Pharmaceuticals says (Marijuana Business Daily)

// Proposed overhaul of Australia’s medical cannabis framework ‘far too slow,’ industry officials say (Marijuana Business Daily)

// Cannabis Control Commission Chairman Steve Hoffman: Lack of money top barrier for social equity applicants (Mass Live)

// Twice as Many Americans Use Cannabis for Medicine Over Recreation, Study Says (Merry Jane)

// NFL legend Calvin Johnson says he used cannabis after every game to relieve pain (Growth Op)

// Judge says nonresidents can obtain New Mexico medical pot (South Florida Sun-Sentinel (AP))


Check out our other projects:
Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement.
Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Taariq Maruzook/Flickr



Source link

Diego Pellicer Worldwide, Inc. Executes Letter Of Intent To Purchase A Marijuana Infused Products Facility In Denver

Diego Pellicer Worldwide, Inc. Executes Letter Of Intent To Purchase A Marijuana Infused Products Facility In Denver

Intent to purchase the facility is an integral component in the company’s commitment to become a vertically integrated cannabis company.

News provided by

Diego Pellicer Worldwide, Inc.

Sep 17, 2019, 09:09 ET

DENVER, Sept. 17, 2019 /PRNewswire/ — Diego Pellicer Worldwide, Inc. (OTCQB: DPWW), the premium marijuana brand and retail development company, today announced that it has executed a letter of intent to purchase a marijuana infused product (MIP) manufacturing facility in Denver. The 2,287 square-foot facility is a brand new, state-of-the-art, division 1/class 1 facility with an office and walk-in vault.

“From cultivation and manufacturing to medical and recreational sales, this latest LOI is a strategic acquisition in our expanded business model  as we become a fully, vertically integrated marijuana company,” said Ron Throgmartin, chief executive officer, Diego Pellicer Worldwide, Inc. “Pending approval from the Colorado Marijuana Enforcement Division, Diego Pellicer Worldwide, Inc. will be able to manufacture premium concentrates and marijuana infused products within its own facility, to ensure only the very best premium marijuana infused products are being offered for sale in our world-class retail locations. This is truly a monumental step forward for the company and a blueprint for expansion of our business in states where public company ownership of medical and recreational cannabis operations are permitted by state law.”

The non-binding letter of intent to purchase the MIP is subject to compliance with the Colorado Marijuana Enforcement Division and House Bill 19-1090. The letter of intent will be followed by a contract once rulemaking for Colorado House Bill 19-1090 has concluded and the Marijuana Enforcement Division has issued regulations guiding the process for public companies and out-of-state investors to apply for cannabis licensing ownership. The completed regulations and application process are expected in November 2019 after the final public comment hearing is held on Oct. 8. Diego Pellicer Worldwide, Inc. has been actively engaged in the rulemaking workgroups, working alongside other stakeholders to assist and help complete the rulemaking process.

Marijuana Infused Production Facility and Equipment
Included in the letter of intent to purchase the MIP is an extensive list of equipment including a cannabis extraction machine with a recovery pump, fumigation hoods, rotary evaporator, rosin press, isolated grind room/flower preparation room, vacuum oven and more.

Premium Quality from Seed to Sale
Diego Pellicer branded stores feature the finest products and concierge quality service in an approachable, world-class environment. Diego Pellicer elevates the cannabis shopping experience with premium products both cultivated and selected by experts, ensuring that no matter the location, customers can count on Diego Pellicer to deliver the same exceptional customer service, outstanding cannabis and competitive pricing.

About Diego Pellicer Worldwide, Inc. (OTCQB: DPWW)
Diego Pellicer Worldwide, Inc. is the premium marijuana brand, retail and management company. In addition to its branded locations in Colorado, the company actively seeks to develop and manage high-end, turnkey cannabis retail stores and grow facilities. When federally legal, DPWW is positioned to become a national, vertically integrated cannabis company. To learn more about how to become a branded Diego Pellicer retailer, cultivator or investor visit www.Diego-Pellicer.com.

Safe Harbor Statement
Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

CONTACTS:

Suzanne Herrick, Fedoruk & Associates, Inc., 612-247-3079, suzanne@fedorukinc.com

Nello Gonfiantini, Diego Pellicer Worldwide, Inc., 775-690-2188, nello@diego-pellicer.com

WEBSITE:

www.diego-pellicer.com

SOURCE Diego Pellicer Worldwide, Inc.

Special Report: Cannabis Researchers, Scientists Confront Vaping-Related Lung Disease Debate

Special Report: Cannabis Researchers, Scientists Confront Vaping-Related Lung Disease Debate

Vitamin E acetate, terpene content and the illicit market are in the spotlight, but plenty of unanswered questions remain.

September 10, 2019

At Diego Pellicer in Denver, Colo., dispensary employees are confronting the question that’s landed on the doorsteps of all cannabis businesses in recent weeks: How should the legal cannabis industry engage the sudden rise in vaping-related illnesses in the U.S.?

With five reported deaths, more than 450 other cases of vaping-related illnesses in 33 states and a rollicking series of headlines in national news media, cannabis business owners and scientists are educating a general public—and an industry—that’s not yet entirely informed on vape technologies, the bioactivities of molecules and compounds in vape products and the disparities between the legal and illicit cannabis markets (and the popular e-cigarette market).

Nick Jack, chief retail officer of Diego Pellicer, says that it’s not so much the potential sales hit that has his company worried—rather, it’s the public education gap that’s become clear this summer.

“We are working with our staff to ensure they understand the testing and regulatory procedures that recreational and medical cannabis oil companies must go through before their products are available on our shelves,” Jack says. “It’s important that we’re able to educate the consumer on product safety and regulatory guidelines that help reduce the chance of an unsafe product reaching the market.”

Read more.

Diego Pellicer Worldwide, Inc. Executes Letter Of Intent To Purchase Cannabis Cultivation Facility In Denver

Diego Pellicer Worldwide, Inc. Executes Letter Of Intent To Purchase Cannabis Cultivation Facility In Denver

Strategic move comes on the heels of news to purchase a cannabis retail location in Denver: Diego Pellicer Worldwide, Inc. advances into direct ownership and operations in cannabis.


News provided by

Diego Pellicer Worldwide, Inc.

Sep 10, 2019, 09:08 ET

DENVER, Sept. 10, 2019 /PRNewswire/ — Diego Pellicer Worldwide, Inc. (OTCQB: DPWW), the premium marijuana brand and development company, today announced that it has executed a letter of intent to purchase a cannabis cultivation facility in Denver. The 13,000 square-foot cultivation facility produces approximately 2,000 pounds of cannabis per year.

“Our intent to purchase this cultivation facility complements our intent to purchase the retail location which we announced last week. We have been evolving our business model, fulfilling our commitment to become a vertically integrated premium cannabis company,” said Ron Throgmartin, chief executive officer, Diego Pellicer Worldwide, Inc. “We look forward to working with the Colorado Marijuana Enforcement Division to garner approval for Diego Pellicer Worldwide to become a fully licensed cannabis company, including the retail operation and now, this cultivation facility.”

The non-binding letter of intent is subject to compliance with the Colorado Marijuana Enforcement Division and House Bill 19-1090. The letter of intent will be followed by a contract once rulemaking for Colorado House Bill 19-1090 has concluded and the Marijuana Enforcement Division has issued regulations guiding the process for public companies and out-of-state investors to apply for cannabis licensing ownership. The completed regulations and application process are expected in November 2019 after the final public comment hearing is held on Oct. 8.

Diego Pellicer Worldwide, Inc. has been actively engaged in the rulemaking workgroups, working alongside other stakeholders to assist and help complete the rulemaking process.

A Premium Diego Pellicer Cannabis Experience Begins with Outstanding Products
Diego Pellicer branded stores feature the finest products, concierge quality service in an approachable, world-class environment. Diego Pellicer elevates the cannabis shopping experience featuring premium products both cultivated and selected by experts, ensuring that no matter the location, customers can count on Diego Pellicer to deliver the same exceptional customer service, premium cannabis and competitive pricing.

About Diego Pellicer Worldwide, Inc. (OTCQB: DPWW)
Diego Pellicer Worldwide, Inc. is the premium marijuana brand, retail and management company. In addition to its branded locations in Colorado, the company actively seeks to develop and manage high-end, turnkey cannabis retail stores and grow facilities. When federally legal, DPWW is positioned to become a national, vertically integrated cannabis company. To learn more about how to become a branded Diego Pellicer retailer, cultivator or investor visit www.Diego-Pellicer.com.

Safe Harbor Statement
Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

CONTACTS:      

Suzanne Herrick, Fedoruk & Associates, Inc., 612-247-3079, suzanne@fedorukinc.com

Nello Gonfiantini, Diego Pellicer Worldwide, Inc., 775-690-2188, nello@diego-pellicer.com

SOURCE Diego Pellicer Worldwide, Inc.

 

Diego Pellicer Worldwide, Inc. Executes Letter Of Intent To Purchase Denver Cannabis Retail Operation

Diego Pellicer Worldwide, Inc. Executes Letter Of Intent To Purchase Denver Cannabis Retail Operation

Latest strategic move is consistent with Diego Pellicer’s commitment to evolve the company’s business model

Diego Pellicer Worldwide, Inc.

Sep 04, 2019, 09:06 ET

DENVER, Sept. 4, 2019 /PRNewswire/ — Diego Pellicer Worldwide, Inc. (OTCQB: DPWW), the premium marijuana brand and development company, today announced that it has executed a letter of intent to purchase a cannabis retail store in Denver. The 3,300 square-foot retail location is projected to have gross sales exceeding $8.5 million in 2019 and $9.5 million in gross sales in 2020.

“This is a critical milestone for Diego Pellicer Worldwide. The execution of the LOI in Colorado is the first step in the evolution of our business model. We are delivering on our commitment to become a vertically integrated premium cannabis company. We look forward to working with the Colorado Marijuana Enforcement Division to garner approval for Diego Pellicer Worldwide to become a fully licensed cannabis company, that includes direct ownership in cannabis operations,” said Ron Throgmartin, chief executive officer, Diego Pellicer Worldwide, Inc. “For Diego Pellicer Worldwide to continue to grow, we need to pursue these new avenues of ownership as well as branded cannabis products that will be available at company stores and beyond its branded retail locations.”

The non-binding letter of intent is subject to compliance with the Colorado Marijuana Enforcement Division and House Bill 19-1090. The letter of intent will be followed by a contract once rulemaking for Colorado House Bill 19-1090 has concluded and the Marijuana Enforcement Division has issued regulations guiding the process for public companies and out-of-state investors to apply for cannabis licensing ownership. The completed regulations and application process are expected in November 2019 after the final public comment hearing is held on Oct. 8.

The Premium Diego Pellicer Cannabis Experience
Whether a new customer or a cannabis connoisseur, Diego Pellicer elevates the cannabis shopping experience, ensuring that no matter the location, customers can count on Diego Pellicer to deliver the same exceptional customer service, premium cannabis and competitive pricing. Diego Pellicer branded stores feature the finest products, concierge quality service in an approachable, world-class environment.

About Diego Pellicer Worldwide, Inc. (OTCQB: DPWW)
Diego Pellicer Worldwide, Inc. is the premium marijuana brand, retail and management company. In addition to its branded locations in Colorado, the company actively seeks to develop and manage high-end, turnkey cannabis retail stores. When federally legal, DPWW is positioned to become a national, vertically integrated cannabis company. To learn more about how to become a branded Diego Pellicer retailer, cultivator or investor visit www.Diego-Pellicer.com.

Safe Harbor Statement 
Certain statements contained in this press release may be construed as “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Act”). The words “estimate,” “project,” “intends,” “expects,” “anticipates,” “believes” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management’s beliefs, as well as assumptions made by, and information currently available to, management pursuant to the “safe-harbor” provisions of the Act. These statements are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. The Company also undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.

CONTACTS:

Suzanne Herrick, Fedoruk & Associates, Inc., 612-247-3079, suzanne@fedorukinc.com

Nello Gonfiantini, Diego Pellicer Worldwide, Inc., 775-690-2188, nello@diego-pellicer.com

SOURCE Diego Pellicer Worldwide, Inc.

Researchers use mobile app to measure how commercially available cannabis products affect pain intensity — ScienceDaily


Using the largest database of real-time recordings of the effects of common and commercially available cannabis products in the United States (U.S.), researchers at The University of New Mexico (UNM) found strong evidence that cannabis can significantly alleviate pain, with the average user experiencing a three-point drop in pain suffering on a 0-10 point scale immediately following cannabis consumption.

With a mounting opioid epidemic at full force and relatively few alternative pain medications available to the general public, scientists found conclusive support that cannabis is very effective at reducing pain caused by different types of health conditions, with relatively minimal negative side effects.

Chronic pain afflicts more than 20 percent of adults and is the most financially burdensome health condition that the U.S faces; exceeding, for example, the combined costs of treating heart disease and cancer.

“Our country has been flooded with an over-prescription of opioids medications, which then often leads to non-prescription opioid and heroin use for many people. This man-made disaster is killing our families and friends, regardless of socio-economic status, skin tone, and other superficial human differences” said Jacob Miguel Vigil, one of the lead investigators of the study, titled “The Effectiveness of Self-Directed Medical Cannabis Treatment for Pain,” published in the journal Complementary Therapies in Medicine.

Vigil explains, “Cannabis offers the average patient an effective alternative to using opioids for general use in the treatment of pain with very minimal negative side effects for most people.”

The researchers relied on information collected with Releaf App, a mobile software program developed by co-authors Franco Brockelman, Keenan Keeling and Branden Hall. The app. enables cannabis users to monitor the real-time effects of the breadth of available cannabis-based products, which are always variable, of course, given the complexity of the Cannabis plant from which these products are obtained.

Since its release in 2016, the commercially developed Releaf App has been the only publicly available, incentive-free app for educating patients on how different types of products (e.g., flower or concentrate), combustion methods, cannabis subspecies (Indica, Sativa, and hybrid), and major cannabinoid contents (THC and CBD) affect their symptom severity levels, providing the user invaluable feedback on their health status, medication choices, and the clinical outcomes of those choices as measured by symptom relief and side effects.

Scientifically, software like the Releaf App enables researchers to overcome the inherent limitations of government-funded clinical trials on the real-time effects of Cannabis, which are rare in general, but also often limited by onerous federal regulations, including its Schedule I status (no accepted medical use and a high abuse potential) and the mandate that investigators use the notoriously poor quality and low potency cannabis products supplied by the National Institute of Drug Abuse.

“Even just rescheduling cannabis just from Schedule I to Schedule II, i.e., classifying it with fentanyl, oxycodone, and cocaine rather than heroin and ecstasy, could dramatically improve our ability to conduct research and only would require that the DEA recognizes that accepted medical uses for cannabis exist, as clearly evidenced by our results and the flourishing medical cannabis programs in the majority of U.S. states,” pointed out co-author Sarah Stith.

Among the study’s findings the greatest analgesic responses were reported by people that used whole dried cannabis flower, or ‘buds,’ and particularly cannabis with relatively high levels of tetrahydrocannabinol, otherwise known as THC. The more recently popularized cannabinoid, cannabidiol or CBD, in contrast, showed little association with the momentary changes in pain intensity, based on the massive database explored in the study.

“Cannabis likely has numerous constituents that possess analgesic properties beyond THC, including terpenes and flavonoids, which likely act synergistically for people that use whole dried cannabis flower,” said Vigil, “Our results confirm that cannabis use is a relatively safe and effective medication for alleviating pain, and that is the most important message to learn from our results. It can only benefit the public for people to be able to responsibly weigh the true risks and benefits of their pain medication choices, and when given this opportunity, I’ve seen numerous chronic pain patients substitute away from opioid use, among many other classes of medications, in favor of medical cannabis.”

“Perhaps the most surprising result is just how widespread relief was with symptom relief reported in about 95 percent of cannabis administration sessions and across a wide variety of different types of pain,” added lead author of the study, Xiaoxue Li.

The authors do caution that cannabis use does carry the risks of addiction and short-term impairments in cognitive and behavioral functioning, and may not be effective for everyone. However, there are multiple mechanisms by which cannabis alleviates pain suffering. In addition to its anti-inflammatory properties, cannabis activates receptors that are colocalized with opioid receptors in the brain. “Cannabis with high THC also causes mood elevation and adjusts attentional demands, likely distracting patients from the aversive sensations that people refer to “pain,” explains Vigil.

“When compared to the negative health risks associated with opioid use, which currently takes the lives of over 115 Americans a day, cannabis may be an obvious value to patients. Chronic opioid use is associated with poorer quality of life, social isolation, lower immune functioning and early morbidity. In contrast, my own ongoing research increasingly suggests that cannabis use is associated with a reversal of each of these potential outcomes,” said Vigil



Source link

Tuesday, August 20, 2019 Headlines | Marijuana Today Daily News


A sun-lit hemp leaf and young bud sits under bright light.

Marijuana Today Daily Headlines
Tuesday, August 20, 2019 | Curated by host Shea Gunther

// Credit Unions Can Bank Hemp Businesses, Federal Agency Announces (Marijuana Moment)

// Oregon Has Way Too Much Legal Weed. This Is Where It’s Going (Vice)

// Marijuana Taxes Differ In Legalized States, Complicating Projections (Marijuana Moment)


Today’s headlines are brought to you by our friends over at Eaze.com, California’s top one stop website for legal marijuana delivery. If you live in the golden state, swing over to Eaze.com to see if they are active in your area. With deliveries taking place in less than an hour, it’s never been easier to get legal California marijuana delivery. And of course, if you don’t live where Eaze delivers, you can still benefit from all the useful bits of industry insight and analysis they’ve developed using their properly aggregate and anonymized sales data stream.


// ‘The system is swamped.’ Canada can’t keep up with requests to study cannabis (Science Magazine)

// Columbia begins shipping CBD to Switzerland (Grizzle)

// Medicine Man Technologies Continues to Execute on Colorado Roll-Up Strategy with Announcement of $17.25 Million Pending Acquisition (New Cannabis Ventures)

// Canadian cannabis investors still waiting for a breakout company to emerge (Growth Op)

// Deschutes County imposes marijuana moratorium (Bend Bulletin)

// Louisiana medical cannabis supplies adequate, state says (Marijuana Business Daily)

// Bernie Sanders Calls For Legalization Of Marijuana And Safe Injection Sites (Marijuana Moment)


Check out our other projects:
Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement.
Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Eljay/Flickr



Source link

Amount rivals what Americans spend on alcohol — ScienceDaily


Spending on cannabis, cocaine, heroin and methamphetamine by Americans reached nearly $150 billion in 2016, with a large proportion of spending coming from the small share of people who use drugs on a daily or near-daily basis, according to a new RAND Corporation report.

Researchers estimate that from 2006 to 2016, the total amount of money spent by Americans on these four drugs fluctuated between $120 billion and $145 billion each year. By contrast, a different analysis finds that spending on alcohol in the U.S. was estimated to be $158 billion in 2017.

Total spending on cannabis, from both illegal and state-licensed sources, increased by approximately 50 percent from 2006 to 2016, from $34 billion to $52 billion. The market for cannabis is roughly the size of the cocaine and methamphetamine markets combined, and the size of the retail heroin market is now closer to the size of the marijuana market than it is to the other drugs, according to the analysis.

“To better understand changes in drug use outcomes and the effects of policies, policymakers need to know what is happening in markets for these substances,” said Greg Midgette, the study’s lead author, an assistant professor at University of Maryland and an adjunct policy researcher at RAND, a nonprofit research organization. “But it is challenging to generate these estimates, and given that critical data sources have been eliminated, it will likely be harder to generate these figures in the future.”

In addition to estimating expenditures on cannabis, cocaine, heroin and methamphetamine, researchers from RAND used a variety of sources of information about drug use and drug prices to also estimate the number of people who use these substances and how much they consume.

The report shows that after falling precipitously from 2006 to 2010, consumption of cocaine continued to fall slowly through 2015, then increased in 2016. Results suggest there were 2.4 million individuals who used cocaine on four more or days in the past month in 2015 and 2016. Results also suggest that consumption grew in 2016 among a stable number of users as the price per pure gram declined.

Consumption of heroin increased approximately 10 percent per year between 2010 and 2016, according to the analysis. Whereas most heroin consumed in the United States comes from poppies grown in Mexico, the introduction of synthetic opioids like fentanyl into heroin markets has increased the risk of using heroin and complicated market analyses.

There was a steady increase in the amount of heroin seized within the United States and at the southwest border from 2007 through 2016. Changes in the composition of heroin users, potentially involving increased use among individuals without criminal histories, have increased the uncertainty underlying these estimates.

From 2010 to 2016, the number of individuals who used cannabis in the past month increased nearly 30 percent, from 25 million to 32 million. Changes in the potency of marijuana and the proliferation of nonflower products such as oils and waxes have made weight-based consumption estimates obsolete and forced a change in how researchers calculate expenditures.

Researchers say their estimates about methamphetamine use are subject to the greatest uncertainty because national data sets do a particularly poor job of capturing its use.

The federal government discontinued a critical data collection effort in 2003, the Arrestee Drug Abuse Monitoring, or ADAM, right before methamphetamine use was believed to be at its first peak during 2004 to 2006.

ADAM not only collected detailed information about drug market transactions from arrestees, it also included a voluntary urine screen that could only be used for research purposes. A limited version of ADAM was brought back in 2007 and then eliminated after 2013, right when methamphetamine consumption was believed to be picking back up.

“While there is considerable uncertainty surrounding national methamphetamine estimates, multiple indicators suggest methamphetamine use has exceeded its previous peak around 2005,” said Beau Kilmer, co-author of the report and director of the RAND Drug Policy Research Center. “While there is much more we can do reduce opioid use disorders and poisonings involving synthetic opioids, we cannot ignore the growing problems associated with methamphetamine use.”

The RAND researchers note that one important step to better address use of methamphetamine and understand all drug markets would be to fund again some version of the ADAM program that covers urban and rural areas.

Support for the study was provided by the Office of Research and Data Analysis within the federal Office of National Drug Control Policy.



Source link